119102-22-6

Basic information

• Product Name: 1-Azabicyclo[2.2.1]heptane-4-carboxylic acid
• CAS NO: 119102-22-6
• Molecular Formula: C7H11NO2
• Molecular Weight: 141.16774
• Mol File: 119102-22-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 190.7±23.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• PKA: 9.17±0.40(Predicted)
• CAS DataBase Reference: 1-Azabicyclo[2.2.1]heptane-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Azabicyclo[2.2.1]heptane-4-carboxylic acid(119102-22-6)
• EPA Substance Registry System: 1-Azabicyclo[2.2.1]heptane-4-carboxylic acid(119102-22-6)

Safety Data

• Hazardous Substances Data: 119102-22-6(Hazardous Substances Data)

Usage

Structure

Bicyclic structure containing a nitrogen atom

Type

Chemical compound

Derivative

Tropane derivative

Usage

Commonly used in the synthesis of pharmaceuticals and agrochemicals

Potential Applications

a. Antimuscarinic drugs for treating asthma and Parkinson's disease
b. Analgesics
c. Anti-addiction medications

Field of Interest

Medicinal chemistry

Unique Features

The compound's unique structure and properties make it a subject of interest in the field of medicinal chemistry.

Upstream product

• 67-56-1 methanol 
• 119103-15-0 1-AZABICYCLO[2.2.1]HEPTANE-4-CARBOXYLIC ACID 
• 17012-21-4 1-benzylpyrrolidine-3-carboxylic acid methyl ester 
• 119102-24-8 ethyl 1-azabicyclo<2.2.1>hept-4-yl carboxylate 
• 119102-90-8 7-benzyl-7-aza-2-oxaspiro<4.4>nonan-1-one 
• 119102-91-9 1-Benzyl-4-ethoxycarbonyl-1-azonia-bicyclo[2.2.1]heptane; bromide 
• 1047675-62-6 1-benzyl-1-azoniabicyclo[2.2.1]heptane-4-carboxylate 

Relevant articles and documents

AZA-BRIDGED-RING COMPOUND

[PROBLEMS] Provided is a compound which has an antagonistic action on a muscarinic M3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [MEANS FOR SOLVING PROBLEMS] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.